Bioniche, Synerx Launch Melphalan Hydrochloride
Launch represents introduction to generic injectable oncology market and underscores
Bioniche and Synerx have announced the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran from GlaxoSmithKline.
Bioniche and Synerx entered into an agreement whereby Synerx developed and secured the FDA’s approval of Melphalan, and Bioniche holds the exclusive rights to market and distribute Melphalan in the US.
George Zorich, President of US Operations, Bioniche Pharma, said: The launch of Melphalan represents Bioniche's introduction to the generic injectable oncology market and underscores our commitment to rapid and aggressive product line growth.
We are pleased to have partnered with Synerx and value their expertise in developing this specialty generic product to meet the needs of cancer patients, he added.
Related Insight
Suppliers Directory
Capsugel - Providing Innovative Dosage Forms and Solutions to Health Care Customers
Capsugel is committed to be the leading provider of innovative dosage forms and solutions to healthcare customers around the world.
Suppliers
EXTEDO - Key Services and Solutions Provider in eRegulatory Affairs
EXTEDO is the key solutions and services provider in the field of eRegulatory Affairs.
Suppliers
ANSYS - Pharmaceutical Engineering Simulation Software
ANSYS, Inc. develops and distributes engineering simulation software capable of reproducing, with great accuracy, numerous processes involved in pharmaceutical, biomedical and biotechnology applications.
Suppliers
Pharmatest Services - Preclinical Contract Research
Pharmatest Services Ltd is a full-service bone biology CRO specialised in preclinical testing of new drug candidates both in vitro and in vivo. We provide cost-effective solutions for fast and high quality preclinical drug efficacy research.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Studying Leukocyte Transendothelial Migration in Detail
Published by Phenom World
White Papers
The Devil is in the Detail!
Published by Vaisala
White Papers
Revolutionary Plasma Technology from Presspart.
Published by Presspart
White Papers
Investigator Resources - US
Published by Investigator Location Services
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.